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Protective adaptation of low serum triiodothyronine in patients with
chronic renal failure. Low serum triiodothyronine (T3) concentration is
frequently found in patients with chronic renal failure (CRF). To test
the hypothesis that this may serve to minimize protein catabolism in
these patients, we measured nitrogen balance (Nb) in seven CRF and
four control subjects in the basal state and when serum T3 concentration
was elevated by L-triiodothyronine (LT3) and suppressed by sodium
ipodate administration. In the basal state, both the controls and the
CRF patients were in positive Nb, 0.02 0.51 and 0.58 0.34 glday,
respectively. During LT3 administration, Nb decreased to —0.80 0.39
g/day in the CRF patients (P < 0.01), but remained positive, 0.22 0.67
g/day, in the controls. There was a significant negative correlation
between serum T3 concentration and Nb in the CRF patients (r =
—0.63, P < 0.005), but not in the controls. Furthermore, urea nitrogen
generation rate, calculated from urea kinetics, increased from a baseline
of 4.6 0.55 to 6.0 0.50mg/mm during LT3 administration in the CRF
patients (P < 0.01). Sodium ipodate, which significantly lowered serum
T3 concentrations, had little effect on nitrogen metabolism in the
controls and the CRF patients. These data support the concept that low
serum T3 concentrations may confer a protective effect on CRF patients
regarding protein-nitrogen conservation and provide a rationale for not
correcting such deficiency.
Adaptation protectrice d'une trilodothyronine sérique basse chez des
malades atteints d'insufllsance rénale chronique. Une concentration
faible de triiodothyronine sérique (T3) est souvent trouvée chez des
malades atteints d'insuflisance rénale chronique (CRF). Afin de verifier
l'hypothése que ce fait pourrait contribuer a minimiser le catabolisme
protéique chez ces malades, nous avons mesurd Ia balance azotée (Nb)
chez sept CRF, et chez quatre sujets contrôles a l'état basal, et lorsque
Ia concentration sérique de T3 était élevée par l'administration de
L-triiodothyronine (LT3), ou supprimCe par celle d'ipodate de sodium.
A l'état basal, les contrôles et les malades CRF avaient une Nb positive,
0,02 0,51 et 0,58 0,34 g/jour, respectivement. Au cours de
l'administration de LT3, Nb a diminué a —0,80 0,39 g/jour, chez les
malades CRF (P < 0,01), mais est restCe positive, 0,22 0,67 gljour,
chez les contrôles. Ii existait une correlation negative significative entre
la concentration sérique de T3 et Nb chez les malades CRF (r = 0,63, P
<0,005), mais non chez les contrôles. Dc plus, la vitesse de generation
de l'azote ureique, calculée a partir de Ia cindtique de l'urée, a
augmente d'une valeur de base de 4,6 0,55 a 6.0 0,50 mg/mm
pendant l'administration de LT3 chez les malades CRF (P < 0,01).
L'ipodate de sodium, qui diminuait significativement les concentrations
sériques de T3, avait peu d'effets sur Ic métabolisme azoté chez les
contrôles et les malades CRF. Ces données sont en faveur du concept
que des concentrations sériques de T3 basses pourraient conférer un
effet protecteur chez les malades CRF en cc qui concerne Ia conserva-
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tion proteique et azotCe, et apportent un argument pour ne pas corriger
ce deficit.
A reduction in serum triiodothyronine (T3) concentration is
well documented in chronic renal failure (CRF) patients [1—4].
The significance of this finding, however, remains speculative.
It has been hypothesized that low serum T3 concentration in
these patients has a biologic function, representing, perhaps, a
metabolic adaptation for energy conservation [5]. In addition,
T3 administration has been advocated by some to increase the
well-being of these patients. We suspect that low serum T3
concentrations in these patients has an important function
because previous work from our group in uremic rats indicated
that T3 deficiency is also present at the tissue level, specificially,
the liver. Moreover, thyroid hormone-dependent enzyme activ-
ity and nuclear T3 receptor-binding capacity are also reduced
[6, 7]. In the current study, we attempted to test the validity of
the above hypothesis and to resolve the controversial issue
concerning T3 administration by measuring nitrogen balance
and oxygen consumption in CRF patients in the basal state and
during periods when serum T3 concentrations were altered by
either L-triiodothyronine (LT3) or sodium ipodate administra-
tion. The former increased and the latter suppressed serum T3
concentrations further [8, 9]. The results showed an increased
nitrogen excretion during LT3 administration and support the
concept that decreased T3 production may, indeed, have a
protective effect in minimizing protein nitrogen catabolism in
patients with renal failure.
Methods
Subjects
The population of the current study consisted of seven CRF
patients and four control subjects. There were four women and
three men in the CRF group whose ages ranged from 20 to 59
years with the mean age being 42.8 6.0 (sEM) years. The
etiologies of their chronic renal failure were as follows: four,
chronic glomerulonephritis; two, congenital urinary tract
obstruction, and one, polycystic kidney disease. Their endog-
enous urea clearance rates ranged from 0 to 0.5 ml/min. Six
patients were treated with hemodialysis and one (RB) with
chronic ambulatory peritoneal dialysis (CAPD). The patients
were selected on the basis of a low serum T3 concentration (at
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least one standard deviation below our mean). In 18 normal
subjects, mean serum T3 concentration 1 SD is 137 26 ng/dl.
Additional criteria for patient selection included: 1) normal
serum TSH concentration (<10 jsU/ml), 2) absence of previous
history of thyroid disease1, 3) clinically stable, and 4) absence of
angina pectoris and congestive heart failure. Their medications
included multivitamins, phosphate binders (alucaps and
alternagel) and dihydrotachysterol. As mentioned in the foot-
note, JS was taking L-thyroxine (LT4) and APL was taking 40
mg/day of propanolol for mild hypertension. The normal control
subjects consisted of three women and one man; their ages
ranged from 25 to 49 and their mean age was 33.0 5.4 years.
The body mass indices (Wt/Ht2) were in the 49 17 and 43
13 percentile, respectively, for the CRF patients and the con-
trols as compared to age and sex-matched normal subjects of
the NHANES-1 Survey [10].
Experimental design
Each participant, control subject as well as CRF patient, was
studied on three separate occasions: in the basal state, during
L-T3 (Cytome®) administration, and during sodium ipodate
(Oragrafin®) administration. Each study period lasted 9 days
and the sequences of the three periods were assigned randomly.
In all seven CRF patients and in three control subjects, LT3 was
given at a total daily dose of 50 jig orally in four equally divided
doses, in one control subject (JH), because of his higher body
weight, LT3 was given at a total daily dose of 75 jig orally in
three equally divided doses. Corrected for body wt, the dosages
of LT3 were 0.78 0.05 and 0.84 0.08 jig/kg, respectively, in
the CRF patients and the controls; the values were not different
statistically. The dose of sodium ipodate was 1 g per day orally.
Both LT3 and sodium ipodate were given for a period of 2
weeks, 1 week before the study and 1 week during the study.
One CRF patient (RB) did not complete the sodium ipodate
study because of the development of pruritic macular rash.
Measurements during each study period included: 1) nitrogen
balance, 2) serum thyroid hormone profile, 3) TRH test, 4) basal
oxygen consumption, and 5) urea nitrogen generation rate (Ge)
in the six hemodialysis patients. The last parameter served to
assess protein catabolic rate independent of nitrogen balance
measurement.
Nitrogen balance study
Figure 1 illustrates the protocol followed by the CRF patients
with regard to diet and the timing of urine and fecal collection
and dialyses. Each patient was admitted to the Clinical Re-
search Center and was placed on a constant diet starting
Sunday morning and continued for at least 9 days until the
following Monday noon. The diet was specifically adjusted for
'JS was taking 0.2 mg of L-thyroxine [LT4, Synthroid®] each day for 6
months, approximately the same duration as her chronic renal failure
and dialysis. We were not certain whether she was truly hypothyroid or
whether she was simply given thyroid hormone replacement because of
low circulating thyroid hormone concentration consequent to uremia. It
is interesting to note that despite a high normal serum total T4
concentration of 9.2 sg/dl, her serum T3 concentration was markedly
reduced at 64 ngldl, and her serum TSH concentration was normal.
Thus, it was decided to study her while she was taking the same amount
of (LT4) in all three periods.
T W T F S S MT
Constant diet
Urine collection
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each subject based on his/her usual intake and dietary habits
which were derived from interviews with the nutritionist as well
as a diary of food intake. The menu plan was discussed
extensively with each subject and once agreed upon was held
constant throughout the three study periods. Sufficient amount
of food was prepared in a whole batch for the entire study.
Since neither the protein nor the energy allotment was different
from their routine intake at home, a long period of equilibration
was not needed. A 7-day urine collection was started Monday
morning and ended the following Monday, the specimens were
pooled and kept refrigerated. A 6-day stool collection was
marked by carmine red ingestion on Monday and Saturday and
was kept refrigerated as well. Hemodialysis was performed
with the AK1O Gambro Delivery System and the Gambro
parallel flow dialyzer 11.5 (Gambro, Barrington, Illinois, USA)
four times during each study. Dialysate obtained on the first
dialysis was discarded and that of the three subsequent ones
were saved. Dialysate outflow from the entire dialysis was
collected in toto into a 120-liter tared container. At the end of
the dialysis, the dialysate was mixed thoroughly and triplicate
50 ml dialysate samples were taken for measurements of
nitrogen and urea nitrogen; the container, together with the
dialysate, were then weighed for dialysate volume determina-
tion assuming a specific gravity of 1.000. Additionally, the
change in body urea nitrogen pool (g/day) was calculated with
the following formula: (SUNf — SUN1) BW1 X 0.6 + (BW —
BWI) SUNf where SUN = serum urea nitrogen (mg/mi), BW =
body weight (kg), i and f represent the initial and the final
points, respectively, of each balance period. This formula
assumes that the volume of distribution of urea is total body
water and that short-term changes in body wt represent changes
in body water. Positive values denote urea N accumulation and
negative ones, urea N loss. There were altogether three sets of
data available for each study period, defined as the end of one
dialysis session to the end of the subsequent dialysis session.
Food not consumed or vomited was recorded and portions of
the diet analyzed separately for nitrogen content. All patients,
except JS, were stable and ingested all meals and snacks.
In the one patient (RB) who was treated with CAPD, body
weight and SUN were determined every morning after draining
off the overnight diaiysate and before instilling the first volume
of fresh dialysate solution. Every bag of dialysate was weighed
after drainage for determination of dialysate volume and dupli-
cate samples were taken for measurements of nitrogen and urea
nitrogen concentration.
In the controls, similar procedures were followed with regard
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FIg. 1. Schematic representation of the protocols used by the CRF
patients. Shown here are the duration of the constant diet and the
schedules of dialysis (D) and urine and fecal collection. First dialysate
was discarded and the subsequent three were used for estimation of
nitrogen balance.
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to menu planning. Like the CRF patients, stool collections were
pooled for a 6-day period. Urine collections were done sepa-
rately each 24 hr for 7 consecutive days. The control subjects
were allowed to take their prescribed meals and collect the
urine and fecal samples at home; the samples were kept
refrigerated. As all the control subjects were hospital workers;
the samples were brought in daily. Each participant was en-
couraged to drink abundant amounts of fluid so as to increase
the accuracy of urine collection. There were seven sets of data
for each study period.
Physical activities varied considerably from person to per-
son. No attempts were made to equalize activities among the
experimental subjects, but each was advised to maintain the
same amount of phsyical activities in all three study periods.
The chronic renal failure patients, although freely ambulatory,
were generally quite sedentary. The control subjects continued
to perform their duties in the hospital and one subject (JA) who
jogged 3 miles each day continued to do so.
Urea nitrogen generation rate (Ga) and urea space (Vurea)
In the six CRF patients who were treated with maintenance
hemodialysis, G was calculated by the methods of Sargent and
Gotch [11, 12]. During each dialysis, urea clearance of the
artificial kidney was determined at 1/2, 1 and 2 hr by measuring
the dialysate out flow rates and the urea N concentrations of the
dialysate out flow and the arterial blood samples. Body wt and
SUN were determined pre- and post-dialysis. The time intervals
between two consecutive dialyses and the duration of each
dialysis were accurately recorded. Residual renal urea N clear-
ance was estimated by a 7-day urine collection and daily urinary
urea N excretion was assumed to be 1/7 of the total output;
SUN was also measured on the days between dialyses. A
computer program was written for calculating urea kinetics
utilizing the above data.
Serum thyroid hormone measurements and TRH test
Serum total T3 concentration (1'T3) was measured 2 hr after
each dose of LT3 and immediately before the next dose for 2
days during LT3 administration; the mean of the former was
designated as the peak and the latter, the trough value. Total T4
and free T4 concentration were measured on the same blood
samples as iT3. During the basal and sodium ipodate periods,
blood samples were taken at the same time as in the LT3 period.
The values from each study period were averaged and the mean
values used in the statistical analysis. For the TRH test,
thyrotropin-releasing hromone, 500 jsg, was given as a single
bolus intravenous injection and blood samples were taken 30
and 15 mm before and 15, 30, 45, 60, 90, 120, and 180 mm after
the injection for measurement of thyroid stimulating hormone
(TSH).
Basal oxygen consumption (BOC)
BOC was measured 10 to 12 hr in the post absorptive state
after the subjects had rested for a minimum of half an hour in a
semi-reclining chair. The room was quiet; the temperature and
lighting were comfortable. Participants were given sufficient
time to become familiar with the equipment and the procedures.
Oxygen consumption was determined with the MEDICAL
GRAPHIC EXCERCISE SYSTEM 2000, which utilized a
waveform breath-by-breath analyzer (Medical Graphics Corp.,
St. Paul, Minnesota, USA). Continuous expired gas samples
were obtained 100 times/sec and P02 measured by a zirconium
high-temperature fuel cell (750°C) 02 analyzer (Model S-3A,
Applied Electrochemistry, Inc., Sunnyvale, California, USA).
The analog outputs of the 02 analyzer were connected to a
Tektronix 4052 computer (Tektronix, Inc., Beaverton, Oregon,
USA) via a multichannel analog-to-digital converter (Medical
Graphics Data Interface 704). During the period of testing, the
expired air was collected for quality control into a 120 liter
Douglas bag and the percentage of 02 measured separately by
the same analyzer [13]. These results were well correlated with
the breath-by-breath measurements.
Laboratory procedures
1) Serum TT4, free T4 and rr3concentrations were measured
by radioimmunoassays using commercially available kits (Clin-
ical Assays, Cambridge, Masschusetts, USA). Serum TSH
concentration was also measured by radioimmunoassay using
antibody prepared by Calbiochem-Behring (San Deigo, Califor-
nia, USA) and iodinated tracer prepared by Radioassay Sys-
tems Laboratories (Carison, California, USA).
2) Total nitrogen (N) concentration in the dialysate, urine,
feces, and food was measured by the modified Kjeldahl method
[14].
3) Urea N concentration was measured with the Technicon
Autoanalyzer using diacetyl monoxime.
The protocols were approved by the Clinic Research Center
Committee and the Committee on Research Involving Human
Subjects of the Veterans Administration Medical Center and
the University of Iowa Hopsitals and Clinics.
Statistical analysis
The calculation of urea nitrogen generation rate and urea
space as well as all statistical analyses were done on the
CLINFO SYSTEM of the Clinical Research Center at the
University of Iowa. All values are reported as means SEM.
Student's t test, paired t test, and analysis of variance were
used to evaluate the significance of the differences between the
two experimental groups and between different test periods
within the same group.
Results
Serum thyroid hormone profile and thyroid-pituitary feedback
Table 1 summarizes the results of the thyroid hormone profile
in the basal state and the changes following LT3 and sodium
ipodate administration. In the basal state, the most important
difference between the CRF patients and the control subjects
was a reduction in the serum concentration of total T3, 79 vs.
111 ng/dl, P < 0.005. Mean serum total and free T4 concentra-
tion were not different from one another. It should, however, be
clarified that one of the CRF patients, JS, was taking 0.2 mg/day
of LT4 during the study, which very likely elevated the mean
serum T4 concentration in the CRF group. When her values
were eliminated from the calculations, mean serum total and
free T4 concentration in the remaining six CRF patients were,
respectively, 7.13 0.34 g/dl and 1.17 0.22 ng/dl. These
values, although lower than those listed in Table 1, are still
statistically not different from those of the controls. Basal
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Table 1. Serum thyroid hormone profile in patients with chronic renal failure and normal subjects in the basal state and during
L-triiodothyronine (LT3) and sodium ipodate administration
Yr4
pgIdl
FT4
ng/dl
TT3
ng/dl
TSHb TSHj.U/ml
CRF patients (7)
Basal 7.42 0.40 1,14 0.15 79 5 5.2 1.6 17.2 5.8
LT3 5.51 0.83* 0.83 0.10* 172 16 134 l5 1.5 0.5 2.9 0.7*
Ipodate 8.89 0.73* 1.31 0.17 66 9* 9.1 2.4* 23.0 6.0*P <0.01 NS <0.001 <0.05 <0.05
Normal subjects (4)
Basal 7.40 0.36 1.56 0.15 Ill 6 2.2 0.3 12.1 1.9
LT3 5.28 0.25* 1.00 0.09 214 l2 180 13 1.0 0.3 1.5 04*
Ipodate 9.60 1.04 1.89 0.22 74 8 2.4 0.5 18.3 2.4P <0.005 <0.05 <0.001 NS <0.001
All values are presented as means SEM. TT4, Fr4, and TT3 refer to total thyroxine, free thyroxine, and total triiodothyronine, respectively.
Parentheses indicate the number of subjects. During LT3 treatment period, TT3 levels are reported as peaks and troughs. TSHb and TSH represent
basal values and peak responses following 500 g of TRH. * and 4indicate P values of < 0.05 and < 0.01, comparing LT3 and sodium ipodate
treatment data to their respective basal values by paired t test. §P values derived from analysis of variance.
Table 2. Nitrogen balance data in patients with chronic renal failure and normal subjects in the basal state and during L-triiodothyronine and
sodium ipodate administration
Nd
UN
Nu Nf pool Nm Nb G Intake/dayVurea Protein Energy
g/24 hr mg/mm liter glkg Kcal/kg
CRF
patients (7)
B
T3
Ip
p*
7.43 0.55
8.60 0.43*
6.60 0.32
<0.05
0.22 0.12 0.93 0.05 0.05 0.19
0.26 0.15 0.99 0.10 0.12 0.14
0.27 0.13 0.84 0.11 0.11 0.15
NS NS NS
9.21 0.83
9.17 0.81
8.70 0.78
NS
0.58 0.34
—0.80 0.39
0.87 0.37
<0.01
4.62 0.55
6.00 O.SO
4.72 0.60
NS
35.4 3.0 0.87 0.06 29.5 1.5
41.1 4.4 0.88 0.06 29.7 1.8
35.0 2.3 0.84 0.07 28.8 2.6
NS NS NS
Normal
subjects (4)
B
T3
Ip0
13.18 0.70 1.52 0.07
12.92 0.53 1.65 0.08
12.88 0.73 1.69 0.30
NS NS
14.72 1.12
14.79 1.12
14.61 0.90
NS
0.02 0.51
0.22 0.67
0.05 0.60
NS
1.57 0.18 39.9 1.3
1.57 0.18 40.3 1.4
1.58 0.18 40.4 1.5
NS NS
All values are presented as means SEM. B, T3 and ip represent basal state, LT3, and sodium ipodate administration periods. Nd, Nu, Nf, and
Nm = nitrogencontent of dialysate, urine, feces, and food and Nb = nitrogenbalance. 1UN pool = changes in body urea pool (see Methods). G,,
and Vurea represent urea N generation rate and urea space, calculated by the methods of Sargent and Gotch [10, 11]. Parentheses indicate the
number of subjects. * and *indicate P values of < 0.05 and <0.01, respectively, comparing LT3 and sodium ipodate administration results with
the baseline data within the same group by paired t test. *P values derived from analysis of variance,
serum TSH concentration and TSH peak responses to TRH
appeared to be slightly higher in the CRF patients, but the
differences were not statistically significant. LT3 administration
raised serum T3 concentration in every subject tested. The peak
fractional increments, 118% in the CRF patients and 93% in the
controls, were not different. Both serum total and free T4
concentration were significantly reduced during LT3 adminis-
tration in the control and the uremic subjects, this was accom-
panied by equally significant suppression of serum basal TSH
concentration and peak TSH response to TRH. Sodium ipodate
significantly reduced serum T3 concentration in both groups;
fractional decrements were 16% in the CRF patients and 33% in
the normal subjects. The lesser magnitude of reduction in the
CRF patients was, perhaps, related to their lower basal values.
Serum total and free T4 concentration increased and TSH
response to TRH became exaggerated.
Nitrogen balance
Table 2 compares the nitrogen balance data of CRF patients
and normal subjects in the basal state and the changes that
occurred during LT3 and sodium ipodate administration. In
CRF patients, nitrogen intake (Nm) was lower than that of the
controls, 9.21 vs. 14.72 g/day, P < 0.005. In the basal state,
total nitrogen output (Nd + NU + NI), 8.63 g/day in the CRF
patients, was also proportionately lower than that of the con-
trols, being 14.70 g/day, P < 0.001. Thus, like the controls,
uremic patients maintained a slightly positive nitrogen balance.
While approximately 89% of the nitrogenous waste was ex-
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Nd Nu Nf UN pool
g/24 hr
Nm Nb G
mg/mm
CRF
patients
Ii B
LT3
7.06
8.55
0.01 0.73
0.01 1.23
0.41
0.12
8.64 0.43
8.83 —1.08
5.30
7.05
JS B
LT3
6.59
9.23
0.42 1.01
0.37 0.68
—0.72
—0.59
7.33 0.03
6.95 —2.74
4.02
5.90
BM B
LT3
8.39
8.82
0 0.93
0.06 1.18
0.29
0.43
10.61 1.00
10.43 —0.07
5.71
6.62
MJ B
LT3
5.53
6.50
0 0.84
0 0.57
—0.05
—0.01
6.15 —0.16
6.46 —0.60
2.65
3.70
JO B
LT3
6.84
8.85
0.85 1.09
1.05 1.22
0.82
0.56
11.79 2.19
11.93 0.25
3.84
5.90
RB B
LT3
10.09
10.21
0 0.89
0 1.06
—0.29
0.21
11.71 1.03
11.42 —0.06
—
—
AL B
LT3
7.50
8.05
0.29 1.00
0.36 0.98
—0.11
0.12
8.26 —0.42
8.18 —1.33
6.20
6.82
Normal
subjects
JH B
LT3
14.74 1.43
13.92 1.60
17.13 0.97
17.24 1.72
PS B
LI3
13.62 1.41
13.61 1.45
15.17 0.14
15.48 0.42
JA B
Li'3
11.39 1.73
11.59 1.81
11.72 —1.40
11.87 —1.53
ER B
LI3
12.97 1.51
12.54 1.76
14.87 0.39
14.56 0.26
creted in the urine in the normal subjects, about 85% was
removed by the dialysate in the uremic patients. Fecal nitrogen
constituted about 10 to 12% of the total nitrogen output in both
groups of subjects although the absolute amount was lower in
the CRF patients. During LT3 administration, nitrogen balance
was well maintained in the normal subjects, By contrast,
nitrogen output increased markedly in the CRF patients, from
8.63 in the basal state to 9.97 g/day. Since nitrogen intake was
almost identical, nitrogen balance became negative, —0.80
g/day. This increase in nitrogen catabolism is accounted for by
nitrogen removal via dialysis because neither the nitrogen
excretion in the urine and the feces nor the urea nitrogen pool
were significantly altered. Upon sodium ipodate administration,
nitrogen balance remained stable in the control subjects. In the
uremic patients, total nitrogen output was 7.82 g/day, a value
lower than that of the basal period. However, since nitrogen
intake was also lower during this period, the mean nitrogen
balance of 0.87 g/day was not different from the basal period.
Also listed in Table 2 are the protein and energy intake as
calculated from the dietary records; both were significantly
lower in CRF patients, P < 0.005. Within each group, both
protein and energy intake, however, were constant for all three
periods.
Table 3 records the individual nitrogen balance data of all
subjects in the basal period and during LT3 administration. In
A : t120 — fl 1110 — r-i-
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Fig. 2. Comparison of nitrogen balance data between the seven CRF
patients (Panel A) and the four normal subjects (Panel B). Changes in
nitrogen content of food (Nm), urine (Nu), feces (NO, and dialysate
(Nd) as well as total nitrogen output (Nt = sum of Nu, Nf, Nd, and
urea N pool) during the LI3 () and sodium ipodate (Ill) administration
periods are presented as percentage of baseline (0), taken as 100%. All
values are presented as means SEM. Only in the CRF patients did Nd
and Nt became significantly increased during LI3 administration, * D <
0.05 and P < 0.01 by paired t test.
the basal period, five CRF patients were in positive nitrogen
balance and in three of them, (BM, JG, and RB), nitrogen
retention was quite substantial, being 1.00, 2.19, and 1.03 glday,
respectively. During LT3 treatment, four of these patients went
into negative nitrogen balance ranging from —0.07 to —2.74
glday. JO, who originally had a positive balance of 2.19 glday,
decreased to 0.25 g/day. MJ and AL were originally in slightly
negative balance and became more severely negative. While
changes in urinary (Nu) and fecal (NI) nitrogen excretion as
well as urea nitrogen pool (UN) were random and insignificant;
increases in urea nitrogen removal by dialysis (Nd) were
consistent in every CRF patient. By contrast, nitrogen balance
in the four control subjects was not altered by LT3 administra-
tion. In three controls, positive nitrogen balance was observed
during both the basal and the LT3 periods, and in one (JA),
comparable negative balances were noted during both periods.
Figure 2 depicts and compares the changes in nitrogen intake
and output in the CRF patients and the normal subjects. Values
obtained in the basal state were taken as 100% and those
obtained during experimental periods were expressed as per-
cent of baseline. Only the mean dialysate nitrogen and the mean
total nitrogen output of the CRF patients increased significantly
to 117 6% and 116 4%, respectively, during LT3 adminis-
tration. In the controls, nitrogen intake and output remained
stable throughout the three periods.
Urea nitrogen generation rate (Ga) and urea space (Vurea)
Urea nitrogen generation rate and urea space were measured
only in the hemodialysis patients and the results are listed in
Table 2. Mean G for the group was 4.62 mg/mm in the basal
state and increased to 6.00 mg/mm during LT3 administration, P
<0.05. During sodium ipodate treatment, G was 4.72 mg/mm.
Table 3. Nitrogen balance data in each individual subject in the basal
state and during L-triiodothyronine administration
(4
B
See footnotes of Tables 1 and 2. For the CRF patients, ND and 4UN
pooi were determined three times per study period and for the controls,
Nu was determined daily for the 7 days of the study period; the mean
values are listed above. B and T3 represent basal and Li'3 periods,
respectively.
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Fig. 3. Relationship between urea nitrogen generation rate (Ga) and
nitrogen removal by dialysis (Nd) in six hemodialyzed CRF patients in
the basal state (0), during LI'3 (s), and sodium ipodate (•) adminis-
tration, showing a significant positive correlation between these two
parameters. (N = 18, r = 0.81, and P < 0.001, = 1.01 x Nd —2.23).
Vurea, however, was not significantly altered by either LT3 or
sodium ipodate administration. As shown in Table 3, G in-
creased in every CRF patient. Figure 3 shows that G correlated
well with nitrogen removal by dialysis (Nd) in the six
hemodialyzed CRF patients (N = 18, r = 0.81 and P <0.001.
= 1.01 x Nd —2.23).
Basal oxygen consumption
The data on BOC are summarized in Table 4. Body mass
index appeared to be higher in the patient group, but the
difference was not statistically significant. Oxygen consumption
in the basal state was not different between the two groups. The
response to LT3 administration, however, was different, the
normal subjects showed an increase in oxygen consumption,
either in absolute values or corrected for body weight or body
mass index. By contrast, the uremic patients showed no incre-
ment. Sodium ipodate appeared to decrease oxygen consump-
tion in both groups of subjects, but this did not achieve
statistical signfiicance when compared to basal values.
Discussion
This study demonstrates that patients with CRF undergoing
dialysis are able to maintain a positive nitrogen balance despite
a lower protein and energy intake than normal subjects. During
LT3 administration, CRF patients developed a less positive or
more negative nitrogen balance whereas nitrogen balance in
normal subjects was unchanged. This differential response to
LT3 administration between the normal controls and the CRF
patients suggests the presence of abnormalities in the interme-
diary protein metabolism of CRF patients, which is character-
ized by increased sensitivity to the catabolic effects of thyroid
hormone.
It could be argued that the amount of LT3 administered in the
present study, 50 tgIday, is higher than the physiologic produc-
tion rate, which is generally estimated to be about 35 to 40
jig/day [15, 16]. Moreover, the mean trough serum T3 concen-
tration of 134 ngldl in the CRF patients during LT3 treatment
Table 4. Basal oxygen consumption in patients with chronic renal
failure and normal subjects in the basal state and during
L-triiodothyronine and sodium ipodate administration
BMI
kgfm2
V02
mI/mm
V02/BW
mi/kg/mm
V02/BMI
mi/mm/kg/rn2
CRF patients (7)
Basal
LI3
Ipodate
P1
26.6 2.7 190 11
186 10
169 13
NS
2.94 0.16
2.90 0.20
2.69 0.22
NS
7.46 0.72
7.40 0.81
6.45 0.70
NS
Normal subjects (4)
Basal
LT3
Ipodate
P1
22.5 1.8 166 30
191 31*
159 26
NS
2,65 0.12
3.08 0.09*
2.56 0.08
<0.05
7.26 0.84
8.40 0.81*
7.00 0.73
NS
See footnote for Table I. BMI = body mass index, BW = body
weight. All values are presented as means SCM. Parentheses indicate
the number of subjects. * = P < 0.005 comparing LI3 to basal value
within each group by paired t test. §P values derived from analysis of
variance.
was not only higher than their own basal value of 79 ng/dl, but
was also higher than the mean basal value of 111 ng/dl in the
controls. Therefore, one would not be surprised to find some
degree of increased catabolism. This argument, however,
should be viewed in light of the observation that equivalent
doses of LT3 in the controls did not produce any catabolic effect
despite achieving an even higher level of mean trough serum
LT3 concentration of 180 ng/dl. Treatment with sodium ipodate
resulted in an easily discernible reduction in serum T3 concen-
tration, a significant rise in serum total and free T4 concentra-
tion, and an exaggerated TSH response to TRH. These findings
are in agreement with those reported by Burgi et al and Kleiman
and his colleagues [8, 9]. In contrast to the changes found in the
serum, sodium ipodate appeared to have little effect on nitrogen
metabolism. In the CRF patients, nitrogen balance became
more positive in three and unchanged in the other three; the
mean value, however, was not different from that obtained in
the basal state.
While nitrogen balance in the normal subjects appeared not to
be affected by LT3 administration, that of CRF patients was
quite sensitive to it. This difference is illustrated in Figure 4 in
which nitrogen balance is plotted against serum TT3 concentra-
tion, which ranged from 43 to 243 ng/dl. In CRF patients (Panel
A), there is a significant negative correlation between these two
parameters, r = —0.629 and P < 0.005. Nitrogen balance
decreased as serum T3 concentrations increased. Nitrogen
balance became negative when serum TT3 concentration ex-
ceeded 125 ngldl (calculated from the linear regression line, Nb
=
—0.013 x serum TT3 + 1.61). In the controls (Panel B), there
was no correlation between nitrogen balance and serum T3
concentration. The three negative balances ranging from —1 to
—1.5 glday were from the same subject who possibly underes-
timated her intake.
The lack of catabolic effect in the controls was not due to
failure of the control subjects to take the prescribed amount of
LT3 because the serum T3 concentration increased and the TSH
response to TRH was suppressed in each control subject.
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creatine excretion increases by tenfold in obese human subjects
when LT3 is administered during fasting compared to that
observed during fasting without LT3 administration [18]. Bur-
man et al recently reported that LT3 administration to obese
human subjects resulted in increased urinary excretion of
3-methyihistidine, [19], a sensitive marker for muscle protein
degradation [203.
Uremia and/or dialysis may also affect protein metabolism. In
experimental models, various groups of investigators, including
Mitch and Clark, Holliday, Garber, and Li and Wassner
[21—25], have demonstrated that uremic rats are more prone to
muscle proteolysis. In vitro preparations of different skeletal
muscle showed an increased release of a-amino nitrogen, amino
acids, as well as 3-methylhistidine, by the uremic rats as
compared to their sham-operated controls during fasting. In
humans, Ganda and colleagues showed that, following
hemodialysis, whole blood and plasma concentrations of the
branched chain amino acids, leucine and isoleucine, remained
unchanged while that of glutamate increased. Since substantial
quantities of these amino acids are removed by dialysis, con-
stant or increasing concentrations were interpreted as evidence
suggestive of enhanced release from muscle [26]. Thus, the
prevailing evidence suggests that, in uremia, the balance be-
tween anabolism and catabolism is shifted towards net protein
catabolism. In addition to vulnerability to fasting, we have
demonstrated in this report an enhanced sensitivity to the
catabolic effects of thyroid hormone, specifically, LT3.
It is not clear whether this enhanced sensitivity to the
catabolic effects of thyroid hormone observed in the CRF
patients is due to uremia per se or, perhaps, related to their
inadequate protein and caloric intake. Borah et al reported that
dialysis patients required about 1.4 g/kg body wt of protein
intake per day to avoid negative nitrogen balance [27]. It should
be emphasized that the intake of our patients was determined
on the basis of their usual dietary habits and no effort was made
to resort to either protein or caloric supplementation. These
intakes are not unique to our patient population and are fairly
accurate reflections of the dietary pattern of most dialysis
patients. A caloric intake of at least 35 Kcal/kg is usually
recommended for CRF patients, especially when the protein
intake is restricted, to achieve some protein-sparing effects [28].
The lower caloric intake of our patients, 30 Kcal/kg, may partly
be responsible for the demonstrated hypersensitivity to thyroid
hormone.
The pituitary-thyroid axis appeared to be entirely normal in
CRF patients, as their responses to LT3 and sodium ipodate
administration were qualitatively and quantitatively similar to
the controls. These findings corroborate very well with our
studies in the rats showing that T3 content in the pituitary of the
uremic rats is normal. In other words, there is no evidence of
hypothyroidism at the pituitary level. In striking contrast, T3
content in the peripheral tissue, as represented by the liver, is
reduced [6, 7]. Although we have no data on tissue T3 content
in the humans, extrapolation of animal model data would
support the concept that peripheral tissue is "hypothyroid" in
the sense that T3 content of the liver or the muscle, if measured,
would probably be reduced. In the uremic rat model, liver T3
content is invariably reduced before a reduction in serum T3 is
noted. This functionally hypothyroid state in the peripheral
tissue serves to defend against protein wasting in a precarious
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Fig. 4. Effect of changing serum TT3 concentrations on nitrogen
balance (Nb) in CRF patients and normal subjects. In CRF patients
(Panel A), low serum TI'3 concentrations obtained in the basal state (0)
and during sodium ipodate treatment (•), were associated with positive
or mildly negative Nb whereas high serum TT3 concentration, achieved
with LT3 () administration, resulted in negative Nb (N = 20, r =
—0.629, and P < 0.005, Nb = —0.013 x serum TI'3 + 1.61). Nb became
negative when serum TT3 concentration exceeded 125 ng/dl, below
which Nb was positive. In the normal subjects (Panel B), there was no
correlation between serum TT3 concentration and Nb (N = 12, r =0.20,
and P = 0.53).
Virtually all the increment in nitrogen output in the CRF
patients during LT3 administration was accounted for by re-
moval in the dialysate, as urinary and fecal nitrogen excretion
were little changed. The changes in urea nitrogen pooi from the
beginning to the end of each period were generally small and
were not different between the basal period and during LT3
administration. This is explained partially by our experimental
design in which both the beginning and the end of each balance
period occurred at the end of a dialysis (Fig. 1), a time when
both the SUN and the body weight were closest to normal.
Urea nitrogen generation rate provided an independent as-
sessment of protein catabolic rate and in the CRF patients it
increased from a basal value of 4.6 mg/mm to 6.0 mg/mm during
LT3 administration. This finding correlated very well with data
obtained from the nitrogen balance technique using the Kjeldahl
procedure.
Negative nitrogen balance in our patients could result from
either a decrease in protein synthesis or an increase in protein
degradation. Our data do not permit us to differentiate between
these two possibilities. However, we speculate that increased
muscle proteolysis may be a key factor because muscle con-
tains the largest fraction of body protein store and increased
muscle catabolism is a feature found in both hyperthyroidism
and uremia.
It is well known that thyrotoxicosis is associated with in-
creased urinary creatine excretion and negative nitrogen bal-
ance [17]. Furthermore, it has been demonstrated that urinary
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situation in which the protein-caloric intake is limited and
catabolism may be exaggerated. Thus, in CRF patients having
low serum T3 concentration, misguided attempts to "replete"
thyroid hormone stores only serve to worsen the situation
because their greater sensitivity to the protein catabolic effects
of thyroid hormone causes them to go into negative or less
positive nitrogen balance. Gardner et al reported similar find-
ings in humans undergoing starvation. In their studies, normal
subjects underwent fasting twice; once without any medication
and a second time while receiving 40 j.g/day of LI3. Urinary
urea nitrogen excretion increased significantly during period of
LT3 administration [29]. Their data and our current results thus
constitute evidence supporting the concept that decreased T3
production during illness may represent a common metabolic
pathway of biologic adaptation for protein-nitrogen conserva-
tion and provide a rationale for not correcting such deficiency.
Basal oxygen consumption was not different between the
normal and the uremic patients. The response to LT3 adminis-
tration, however, was different; while oxygen consumption
increased in the normal subjects, it remained unchanged in the
uremic patients. This resistance to thyroid hormone with regard
to oxygen consumption was unexpected, especially in view of
the sensitivity of protein catabolism to the same hormone. In
the rat, Wimpfheimer and his co-workers found that starvation
resulted in a lower resting oxygen consumption that increased
very sluggishly during thyroid hormone treatment [30].
On the one hand, our patients showed enhanced sensitivity to
thyroid hormone with regard to protein catabolism; on the other
hand, their response to LT3 in terms of oxygen consumption
was blunted. This dichotomy of response to the same hormone,
while puzzling, is not unexplainable. Enhanced sensitivity with
regard to protein catabolism may be related to a number of
potential causes, including insulin resistance, hypergiucagone-
mia, inadequate nutritional intake, and others. Failure of LT3 to
increase oxygen uptake in the uremic patients may be related to
anemia or uremia per se.
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